Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sonidegib + paclitaxel
- Development stage
- Phase 1
- Lead developer
- Sun Pharma
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Sonidegib (LDE225) is an orally bioavailable small molecule inhibitor of the Smoothened (SMO) receptor, a key component of the Hedgehog (Hh) signaling pathway. Paclitaxel is a taxane-based chemotherapy agent that stabilizes microtubules, thereby interfering with cell division and inducing apoptosis. The combination of sonidegib and paclitaxel has been investigated in Phase I clinical trials, notably by the Swiss Group for Clinical Cancer Research (SAKK), for the treatment of advanced solid tumors and platinum-resistant ovarian cancer. The rationale for this combination is to target the Hedgehog pathway, which is often aberrantly activated in various cancers and contributes to tumor progression, maintenance of cancer stem cells, and resistance to conventional chemotherapy.
- Other names
- LDE225 + paclitaxelsonidegib phosphate
02
Targets
SMO (Smoothened)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on sonidegib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sonidegib + paclitaxel.